Report
Oscar Haffen Lamm

BioInvent: Initiating coverage on a rising force in immuno-oncology with a robust pipeline

BioInvent is a Swedish immuno-oncology company backed by a strong R&D platform that has been validated over the years through multiple strategic partnerships with leading pharma companies. Two lead assets, BI-1808 (anti-TNFR2) and BI-1206 (anti-FcyRIIB), are progressing through clinical trials,
Underlying
BIOINVENT INTL AB

Provider
Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Analysts
Oscar Haffen Lamm

ResearchPool Subscriptions

Get the most out of your insights

Get in touch